1. Lioton_SmPC_Ott 16 QRD template
2. Lioton_PIL_Ott ‘16 QRD template
3. Stüttgen G., Bauer E. The permeation of heparin through human skin. Acta Therap 1990; 16:265-76
4. Colombo L.. et al., Clinical experience with a gel containing heparin in high concentration (Lioton 1000 gel – Menarini) in minor sports injuries. Med. Sport. 1986; 39:279-283
5. De Angelis CP., et al., Clinical evaluation of the effectiveness and tolerance of heparin as a topical therapy in vascular diseases. Antolog Med Ital 1985; 5:524-7
6. Milio G. et al., Use of heparin sodium in the form of a gel in venous disorders of the lower limb marked by inflammation. Acta Cardiol Medit 1985; 3:283-8
7. Zesch A, Schaefer H., Penetration, permeation and resorption of heparin. In vivo studies on human skin. Arzneimittelforschung, 1976; 26(7):1365-8.
8. Herold G. und Mitarbeiter, Innere Medizin, Köln: Herold, 2014, S. 820f
9. Bihari I, Survey of the therapeutic effect of heparin gel (Lioton) in superficial phlebitis. Vasc Dis 2001; 8:19-24
10. Pschyrembel, Klinisches Wörterbuch (1986): 255. Auflage, Verlag Walter de Gruyter, Berlin
11. Marrapodi E, et al. The usefulness of percutaneous heparin management in the phlebological therapy. G Ital Angiol 1986; 6:115-22
12. Krück F, Pathophysiologie, Physiologische und pathopysiologische Grundlagen Innerer Erkrankungen, 1988, Urban & Schwarzenberg
13. Texas Heart Institute THI_Incredible_Machine_Cardiovascular_System; http://www.texasheart.org/HIC/Anatomy/, Updated August 2016; Last accessed: 5 April 2017
14. Bux J and Sachs UJH,The pathogenesis of transfusion-related acute lung injury (TRALI), British Journal of Haematology, 2007, 136, 788–799
15. Nicolaides A, et al., Management of chronic venous disorders of the lower limbs – guidelines according to scientific evidence. Int Angiol. 2014 Apr;33(2):87-208
16. Beebe-Dimmer JL, et al., The Epidemiology of Chronic Venous Insufficiency and Varicose Veins Ann Epidemiol. 2005 Mar; 15(3):175-84
17. Sukharev II and Vlajkov GG, The treatment of the acute and chronic venous insufficiency of the lower extremeties with application of the gel Lioton-1000, Klin Khir. 1999; (6):5-6
20. Navratilova, Z. Local Application of Heparin – Feasibility of Its Use in Phlebology Article in Ces.-slov. Derm. (Cesko-slovenska dermatologie), 75, 2000, No. 5, pp. 230-232, under the rubric “Therapy”]
21. Daróczy J. Effects of Lioton gel in varicose syndrome of the lower extremity. Érbetegségek 2002; 3: 85-90.
22. Marrapodi E et al. The usefulness of percutaneous heparin management in the phlebological therapy. G Ital Angiol 1986;6:115-22.
23. Colonna CV., et al. Pharmacovigilance report on a topical heparin preparation. Farmaci 1987; 4: 95-103.
24. Zieliński M., et al. Assessment of sodium heparin gel efficacy in combined in the combined conservative treatment of advanced chronic venous insufficiency. Leczenie Ran 2009;6(1):1—6
25. Jaques LB. Heparins – anionic polyelectrolyte drugs. Pharmacol Rev 1979; 31: 99-167.
26. Hamaad A. et al. Ximelagatran: The future in anticoagulation practice. Br J Cardiol 2004; 11: 229-34.
27. Tyrell D et al. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci 1995; 16: 198-204.
28. Elsayed E, Becker RC. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis 2003; 15: 11-8.
29. Nazarov GF et al. Mechanism of the antiexudative action of heparin. Biull Eksp Biol Med 1979; 87: 304-5.
30. D. Hofman, T.J. Ryan, F. Arnold, G. W. Cherry, C. Lindholm, M. Bjellerup, and C. Glynn, Pain in venous leg ulcers, Journal of Wound Care 1997
31. https://www.nice.org.uk/guidance/cg168/evidence/varicose-veins-in-the-legs-full-guideline-pdf-191485261, (last visited 10.2018)
32. Callam MJ, Epidemiology of varicose veins. Br J Surg. 1994 Feb;81(2):167-73.
33. Antani MR and Bhimji SS, Varicose Veins, Treasure Island (FL): StatPearls Publishing; 2018-. 2017 Nov 21. https://www.ncbi.nlm.nih.gov/pubmed/29262112
34. Kakkos et al. Seasonal variation in the incidence of superficial venous thrombophlebitis. Thromb Res. 2010 Aug;126(2):98-102.
35. Neglen P., “Prevention and treatment of venous ulcers in primary chronic venous insufficiency” Journal of vascular surgery, 2010
36. https://www.mayoclinic.org/diseases-conditions/varicose-veins/diagnosis-treatment/drc-20350649 (last visited 10.2018)
37. Poredos P. et al., . Heparin promotes recanalization of venous thrombotic occlusions. Int Angiol. 2018 Aug;37(4):261-268.
38. Antani MR and Bhimji SS. Varicose Veins. SourceStatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018-. 2017 Nov 21.
39. Darvall KA,et al. J Vasc Surg. 2009 May;49(5):1235-41. doi: 10.1016/j.jvs.2008.12.017.
40. Jones RH, Carek PJ. Am Fam Physician. 2008 Dec 1;78(11):1289-94. Management of varicose veins.
41. Bunick CG. and Aasi SZ., Hemorrhagic complications in dermatologic surgery, Dermatol Ther. 2011 Nov-Dec; 24(6):
537–550.42. https://www.health.harvard.edu/pain/10-tips-to-prevent-injuries-when-you-exercise (last visited 10.2018)
43. http://www.hematology.org/Patients/Clots/Travel.aspx (last visited 10.2018)
44. Tew GA et al. Eur J Appl Physiol. 2018 Feb;118(2):321-329. doi: 10.1007/s00421-017-3772-0. Epub 2017 Dec 2. Effects of supervised exercise training on lower-limb cutaneous microvascular reactivity in adults with venous ulcers.
45. Narayana H, et al., Mater Sci Eng C Mater Biol Appl. 2018 Oct 1;91:263-273. doi: 10.1016/j.msec.2018.05.026. Epub 2018 May 7.b Designing of advanced smart medical stocking using stress-memory polymeric filaments for pressure control and massaging.
46. Cavezzi A et al., Phlebology. 2018 Jan 1:268355518776127. doi: 10.1177/0268355518776127. Compression with 23 mmHg or 35 mmHg stockings after saphenous catheter foam sclerotherapy and phlebectomy of varicose veins: A randomized controlled study.